Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|Locally Advanced Breast Cancer|Luminal A Breast Cancer|Luminal B Breast Cancer
Interventions: DRUG: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|DRUG: Goserelin
Sponsor: University Hospital, Akershus
Collaborators: Novartis|Vestre Viken Hospital Trust